Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002428 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

A Phase 1 study of HIV Infections, sponsored by United Biomedical.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00002428: Completed Phase 1 study of HIV Infections, sponsored by United Biomedical.

NCT00002428 is a Phase 1 study of HIV Infections that has completed, run by United Biomedical. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002428, a Phase 1 study of HIV Infections, has completed, sponsored by United Biomedical.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk HIV-negative volunteers.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL HIV-1 Peptide Vaccine, Microparticulate Monovalent
  • BIOLOGICAL rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine

Study Locations (1)

California

  • Univ of California at San Francisco Gen Hosp - San Francisco

Trial Details

FieldValue
Phase Phase 1
United Biomedical

2 total trials

What the finished NCT00002428 record still lists

NCT00002428 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which HIV-1 Peptide Vaccine, Microparticulate Monovalent is the first listed.

NCT00002428 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002428 about?

NCT00002428 is a clinical study titled "A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects". To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk H...

What is the current status of trial NCT00002428?

This trial is currently completed. It is a Phase 1 study.

What conditions does trial NCT00002428 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002428?

The interventions under investigation include: HIV-1 Peptide Vaccine, Microparticulate Monovalent (BIOLOGICAL), rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002428?

This trial is sponsored by United Biomedical, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002428 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002428, the US trial registry maintained by the National Library of Medicine. NCT00002428 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.